Phase 1/2a, First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT411 as a Monotherapy in Patients With Solid Tumors and in Combination With Atezolizumab, Carboplatin and Etoposide in Patients With Chemotherapy-naïve Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Latest Information Update: 21 Mar 2025
At a glance
- Drugs BNT 411 (Primary) ; Atezolizumab; Carboplatin; Etoposide
- Indications Bladder cancer; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors BioNTech
Most Recent Events
- 02 Aug 2024 Status changed from active, no longer recruiting to discontinued.
- 26 Apr 2024 This trial has been discontinued in Spain according to European Clinical Trials Database record
- 04 Apr 2024 This trial has been suspended in Germany.